Skip to Content

Third COVID-19 Vaccine Shows Effectiveness

MONDAY, Nov. 23, 2020 -- On Monday, AstraZeneca announced that late-stage clinical trials of its COVID-19 vaccine showed it to be 70.4 percent effective, The New York Times reported.

The trials were conducted in the United Kingdom and Brazil in collaboration with the University of Oxford. The AstraZeneca vaccine becomes the third vaccine to show good effectiveness, following on the heels of promising data on vaccines from Pfizer and Moderna. Both of the latter two vaccines had effectiveness around 95 percent.

The AstraZeneca results were based on data for two dosing regimens for the vaccine: One regimen showed an effectiveness of 62 percent, the company said, while the other showed 90 percent effectiveness.

The regimen showing 90 percent effectiveness involved a first dose given at half strength and a second dose given at standard strength. No severe cases of COVID-19 emerged among any recipients, and there was a reduction in asymptomatic infections, suggesting that the vaccine was reducing transmission of the virus, AstraZeneca said, according to The Times.

The New York Times Article

© 2021 HealthDay. All rights reserved.

Posted: November 2020

Read this next

Bamlanivimab + Etesevimab Reduces SARS-CoV-2 Viral Load

FRIDAY, Jan. 22, 2021 -- Treatment with bamlanivimab and etesevimab, but not monotherapy with bamlanivimab, is associated with a reduction in severe acute respiratory syndrome...

Total Pediatric ED Visits Decreased in 2020 Versus 2018, 2019

FRIDAY, Jan. 22, 2021 -- There was a decrease in the total number of pediatric emergency department visits in 2020, but the proportion of trauma-related visits increased,...

2.3 Percent of Kindergarteners Not Up to Date With MMR in 2019-2020

THURSDAY, Jan. 21, 2021 -- Overall, 2.3 percent of kindergarteners were not up to date with measles, mumps, and rubella (MMR) vaccination and did not have an exemption in the 2019...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.